Abatacept fails to provide benefit in relapsing-remitting MS

Results from the double-blind, randomized, placebo-controlled phase II ACCLAIM study indicate that abatacept has no effect on reducing the number of new gadolinium-enhancing lesions on MRI in...
Source: Clinical Neurology News - Category: Neurology Source Type: news